In the SURPASS‑CVOT randomized trial comparing tirsepatide with dulaglutide in patients with type 2 diabetes and atherosclerotic cardiovascular disease, the primary composite end-point (cardiovascular death, myocardial infarction or stroke) was similar in both groups, with tirsepatide meeting the assumption of non-inferiority to dulaglutide (HR 0.92; 95% CI 0.83–1.01). [2][5] The study enrolled more than 13,200 patients (SURPASS‑CVOT) and the analysis showed that the incidence of MACE was 8% lower with tirzepatide, which met criteria for non-inferiority to dulaglutide, but the confidence interval included unity (0.83–1.01). [2] Tirzepatide also demonstrated significantly better secondary outcomes compared to dulaglutide, including greater reductions in HbA1c and greater weight loss; however, these secondary outcomes were not correctly adjusted for type I risk in multiple comparisons. [2] In addition, better outcomes for all-cause mortality and renal function were reported in favor of tirzepatide, with these differences being statistically significant in preliminary reports (not adjusted for multiplicity of trials). [2] The safety profile of tirzepatide was comparable to dulaglutide in the study; no increased risk of serious adverse events or mortality was found in previous pooled analyzes of the SURPASS program. [1][5] Complete data and full results were planned for presentation and publication according to the manufacturer; the first press releases and reports from professional media summarized the main high